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PL-010 A radioimmunoassay (RIA) for human
phospholipase B-precursor (PLB-P), a biological
marker for neutrophil activities
Shengyuan Xu*, Per Venge. Akademiska Sjukhuset, Uppsala,
Sweden
Background: Human phospholipase B-precursor (PLB-P) is a
newly identiﬁed protein from human neutrophils. Its existence in
neutrophils and enzymatic activity against phospholipids suggest
a role in the defence against invading microorganisms. This study
is to investigate the expression of PLB-P in various human tissues
and exploit its clinical relevance.
Methods: Polyclonal antibodies were obtained by immunization
of rabbits with puriﬁed PLB-P. Radio-immunoassay was generated
and used to measure the serum PLB-P levels from patients with
acute bacterial and inﬂuenza A infections.
Results: Immunohistochemical staining of human normal and
malignant tissues were investigated. The adrenal gland, subtypes
of bone marrow poietic cells and neuronal cells showed strong
nuclear and cytoplasmic staining. The serum PLB-P levels were
highly elevated in all of patients with bacterial infections and
in 50% of inﬂuenza A infected patients with complications (in-
ﬂuenza with pneumonia and a bacterial infection). The serum
PLB-P levels were positively correlated with the numbers of
leukocytes (n = 65, r = 0.36, p < 0.003), neutrophils (n = 54, r
= 0.33, p < 0.01) and the surface expression of CD64 (n = 51,
r = 0.40, P < 0,005) on the neutrophils in inﬂuenza A infected
patients with complications.
Conclusions: A speciﬁc, accurate and reproducible radioim-
munoassay for PLB-P was developed. The PLB-P serum levels
reﬂect the neutrophil activity in vivo. The speciﬁc antibodies
and the assay will aid in the elucidation of the function of PLB-P
in future.
Plenary Presentation 11 – Tuberculosis/Respiratory
Tract Infections
PL-011 Promoter and structural gene polymorphisms of
mannose-binding lectin, MBL serum levels and
susceptibility to tuberculosis
Feifei Wang*,1, Wenhong Zhang1, Honghai Wang2,
Xinhua Weng1. 1Department of Infectious Disease, Huashan
Hospital, Fudan University, Shanghai, PR China; 2State Key
Laboratory of Genetic Engineering, Institute of Genetics, School
of Life Science, Fudan University, Shanghai, PR China
Objectives: Mannose-binding lectin plays an important role in
innate immunity. To obtain population with latent tuberculosis in-
fectious (LTBI) as one of subjects of susceptibility to tuberculosis
by ELISPOT technique. In addition, to elucidate the associa-
tion between polymorphisms of MBL gene and susceptibility to
tuberculosis in Chinese Han population.
Methods: T-SPOT TB kit was employed to identify LTBI from
287 persons who were intimately contact with tuberculosis (TB)
patients. We typed the polymorphisms of six SNP (-550 L/H, -221
Y/X, +4 P/Q, 52 A/D, 54 A/B, ‘57 A/C) of MBL gene. The MBL
serum levels were detected by ELISA method. We selected 139
TB patients, 124 LTBI population and 155 healthy controls (HC) to
act as research subjects of susceptibility to tuberculosis.
Results: The result of ELISPOT showed there were 125 persons
with LTBI among 287 persons. The ELISPOT positive rate was
43.6% (125/287). There were obviously differences in the MBL
expression levels of three groups (TB, HC and LTBI groups),
P=0.001. The comparison results between TB group and HC group
shown -550 GG genotype in male was signiﬁcantly associated
with protection from tuberculosis, O R =0.42, 95% CI = 0.20-0.86,
P=0.019.
Conclusion: MBL polymorphisms and serum MBL levels could be
associated with susceptibility to TB infection in Chinese Han
population. There were no differences in MBL polymorphisms
distribution between LTBI population and health controls. MBL
polymorphisms might affect susceptibility to tuberculosis by
effect on the expression of MBL gene.
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